Skip to main content
. 2021 Jul 19;16:319. doi: 10.1186/s13023-021-01950-x

Table 1.

Clinical and demographic characteristics of LAMA2-related muscular dystrophy cohort

LAMA2-CMD LGMDR23
Age of onset, median (range), months 0.0 (0.0–6.0) 18.0 (13.0–156.0)
Age of last follow-up, median (range), years 6.4 (0.3–27.3) 8.2 (3.2–27.0)
Male, % (n) 62.1 (72/116) 50.0 (7/14)
Survivors, % (n) 80.2 (93/116) 92.9 (13/14)
Ambulation alone over 1.5 years old, % (n) 18.4 (18/98) 100 (14/14)
Regression of motor function, % (n) 31.2 (34/109) 7.1 (1/14)
Spinal deformity, % (n) 48.6 (54/111) 7.1 (1/14)
Central nervous system involvement
 Cognitive impairment, % (n) 10.3 (12/116) 0.0 (0/14)
 Seizure, % (n) 9.5 (11/116) 35.7 (5/14)
 Typical brain white matter alterations, % (n) 92.2 (95/103) 69.2 (9/13)
Respiratory involvement
 Neonatal respiratory difficulty, % (n) 7.7 (9/116) 0.0 (0/14)
 Breathing difficulty during follow-up, % (n) 26.9 (29/108) 0.0 (0/14)
Feeding
 Neonatal feeding difficulty, % (n) 25.8 (30/116) 0 (0/14)
 Chewing difficulty over 2 years old, % (n) 65.1 (53/90) 0.0 (0/14)
 Swallowing difficulty over 2 years old, % (n) 65.1 (11/90) 0.0 (0/14)

LAMA2-CMD LAMA2-related congenital muscular dystrophy, LGMDR23 limb-girdle muscular dystrophy-23